VitaCig, Inc. Welcomes Results of UC London Study of Electronic Cigarettes
May 23 2014 - 8:01AM
VitaCig, Inc. and mCig, Inc. (Stock Symbol:MCIG) Company welcomes
the release of the results of University College London's five-year
survey of nearly 6,000 smokers in England. According to the study's
results, which were published in the journal Addiction, respondents
attempting to quit smoking without professional help had an odds of
success approximately 60% higher if they used e-cigarettes than if
they used willpower alone or over-the-counter nicotine replacement
therapies such as patches or gum.
In a press release announcing the study's findings, the authors
also note that, in England, smoking rates are declining, quitting
rates are increasing, and regular e-cigarette use among newer
smokers is negligible. The same release also notes that, while the
authors track the issue "very closely," they have seen no evidence
that electronic cigarettes could "re-normalize smoking."
To read the report in its entirety visit:
http://onlinelibrary.wiley.com/doi/10.1111/add.12623/abstract
VitaCig, Inc. which has developed a $2 vitamin-infused,
nicotine-free alternative to traditional e-cigarettes believes the
results of this study are helpful in addressing some of the recent
concerns surrounding the electronic cigarette industry from the
anti-smoking lobby.
"The idea that, inhaling vapor from a device resembling a
traditional cigarette, is somehow the same as inhaling tar,
tobacco, smoke, or carcinogens is scientifically incorrect. Vapor,
is chemically identical to steam while smoke, is the byproduct of
combustion. With VitaCig, we have supplemented nicotine with
vitamins and smoke with vapor while providing the same
hand-to-mouth activity that is in our view, at the heart of the
traditional smoking experience. We hope that the study published
yesterday will help shape the conversation going forward and
re-introduce the merits of this innovative technology. Industry
watchers should keep in mind that global e-cigarette adoption has
occurred at a faster rate than mobile phone adoption. In my
personal view, this would not have transpired unless e-cigarettes
were providing a utility for traditional smokers in their pursuit
of harm-reduction." Said Paul Rosenberg, CEO of mCig, Inc. About
VitaCig, Inc. VitaCig, Inc. is a technology company that is
harnessing mobile vaporization technology for medical delivery
applications. The company has launched its first consumer
product: The VitaCig, a $2 nicotine-free device that looks and
feels like an electronic cigarette (eCig). Unlike a traditional
eCig, the VitaCig delivers a vapor of natural flavors, vitamins,
and phytonutrients. Initially the VitaCig will be produced in three
flavor categories: Relax, Refresh, Energize with plans for
additional flavor categories and targeted medical applications in
the future. The company is currently a subsidiary of mCig, Inc.
(Stock Symbol:MCIG) that is in the process of being spun-off to
shareholders in 2014.
The traditional tobacco industry is estimated at nearly $900
Billion a year. Financial analysts from Wells Fargo, Goldman Sachs,
and Citigroup predict that by 2022 Electronic Cigarettes will
supplant the traditional tobacco industry and eventually grow into
a $1 Trillion industry.
VitaCig is disrupting both the traditional tobacco industry and
the growing electronic cigarette industry by appealing to the
existing 1.2 Billion adults globally that smoke cigarettes,
providing them with a nicotine and tobacco-free alternative that
may assist in harm reduction. Moreover, the company is expanding
the target market beyond the 1.2 Billion adults by appealing to
non-smokers or occasional smokers with a superior method for the
consumption of Vitamins, Nutrients, and other compounds with
medicinal efficacy. – To learn more visit:
http://www.vitacig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement Any statements contained in this press
release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but
are subject to a number of risks and uncertainties. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products based on its technology; the expected benefits
and efficacy of the Company's products and technology; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
and future product commercialization; and the Company's business,
research, product development, regulatory approval, marketing and
distribution plans and strategies.
CONTACT: Paul Rosenberg
CEO
(425)462-4219